Artelo Biosciences Inc
Company Profile
Business description
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
Contact
505 Lomas Santa Fe
Suite 160
Solana BeachCA92075
USAT: +1 858 925-7049
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
6
Stocks News & Analysis
stocks
AI stocks winners, laggards and losers for 2025
stocks
12 picks for an income portfolio - Q4 2025 update
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,085.90 | 18.70 | 0.21% |
| CAC 40 | 8,362.09 | 118.63 | 1.44% |
| DAX 40 | 25,261.64 | 134.18 | 0.53% |
| Dow JONES (US) | 49,504.07 | 237.96 | 0.48% |
| FTSE 100 | 10,124.60 | 79.91 | 0.80% |
| HKSE | 26,442.30 | 210.51 | 0.80% |
| NASDAQ | 23,671.35 | 191.33 | 0.81% |
| Nikkei 225 | 51,939.89 | 822.63 | 1.61% |
| NZX 50 Index | 13,665.35 | 30.90 | -0.23% |
| S&P 500 | 6,966.28 | 44.82 | 0.65% |
| S&P/ASX 200 | 8,751.40 | 17.80 | 0.20% |
| SSE Composite Index | 4,151.14 | 30.71 | 0.75% |